The abstract is read at the publisher; the summary is JClub's.
Exogenous urocortin-3 in the isolated perfused mouse pancreas stimulates somatostatin secretion and inhibits glucagon secretion, with both effects requiring CRHR2 signaling.
- Why it matters: Glucagon secretion is impaired in type 1 and type 2 diabetes, but how beta-cell signals coordinate delta- and alpha-cell hormone release is not fully defined.
- What they did: Using isolated perfused mouse pancreata, the study applied selective SSTR and CRHR2 antagonists to test UCN-3’s pathway, then assessed endogenous UCN-3 during acute (3.5–10 mM) and sustained hyperglycemia and in streptozotocin-treated mice.
- The result: SSTR blockade abolished UCN-3’s glucagon-inhibiting effect, and CRHR2 antagonism prevented UCN-3-driven SST release and glucagon inhibition; endogenous UCN-3 supported acute hyperglycemia-linked SST and glucagon responses, but sustained hyperglycemia effects on glucagon were not altered.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.